We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

HYCOR BIOMEDICAL

HYCOR offers a comprehensive line of systems and testing products for in-vitro allergy and autoimmune disorders, incl... read more Featured Products: More products

Download Mobile App





Hycor Demonstrates Noveos Immunoanalyzer that Sets New Standards to Limit Impact of Interference

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: Hycor Demonstrates Noveos Immunoanalyzer that Sets New Standards to Limit Impact of Interference (Photo courtesy of Hycor Biomedical)
Image: Hycor Demonstrates Noveos Immunoanalyzer that Sets New Standards to Limit Impact of Interference (Photo courtesy of Hycor Biomedical)

Hycor Biomedical (Garden Grove, CA, USA) demonstrated its new NOVEOS immunoanalyzer at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Every year, the global laboratory medicine community comes together at AACC to collaborate and create system-wide changes that improve patient outcomes and enhance the quality of life for all. The exhibition provides a platform to connect with the industry leaders making ground-breaking advancements in laboratory medicine, including clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, and lab management.

The NOVEOS immunoanalyzer has been designed to overcome challenges confronting laboratories routinely testing for allergen-specific IgE to aid in the diagnosis of allergic diseases. The system was designed to address common issues laboratorians face with current technologies by offering several innovative features, including a significant reduction in sample size, reduced blood-based interferences, less variability within allergen lots, increased accuracy and improved walk-away time for laboratory technicians.

NOVEOS IgE chemiluminescent immunoassay uses streptavidin-coated magnetic beads, a biotinylated capture allergen, serum sample and monoclonal anti-human IgE antibody. Only 4µL of patient sample volume is required which can be especially important in pediatric and geriatric sampling where it may be more difficult to retrieve larger samples. On-board reagents supply sufficient capacity for up to eight hours of continuous testing. This eliminates the need to continuously replenish materials throughout a typical work day. It allows maximum walk away time for laboratory technicians by allowing up to 75 tests per specific allergen and up to 140 allergens on the system at any time.

Many of the unrefined extracts that are used in skin-prick testing and competitive allergy assays generate less reliable patient results due to their complexity. As the allergen industry moves to more highly enriched or standardized extracts, the NOVEOS system has incorporated these materials to provide more consistent and accurate results. The advanced micro-particle technology limits interference from: Biotin, IgG / IgG4, and solid-phase related cross-reactive carbohydrate determinant (CCD). NOVEOS offers high sensitivity, excellent low-end precision and operates for up to 13 hours of true walk-away capability.

Related Links:
Hycor Biomedical 

Automated ELISA-IFA-BLOT Processor AP 22
New
Platinum Supplier
Hormonal Test
Endocrine Array
New
Single-Channel Coagulation Analyzer
Biobas 10
New
3-Part Diff Hematology Analyzer
HEMIX 3-60

Print article
AACC

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio's Belgian Acquisition Targets Neurodegenerative Diagnostics

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.